Safety interpretation / C-028
Known risks versus unknown risks
Silence has several meanings. It may reflect reassuring data, weak surveillance, too little exposure or no suitable human study at all.
A known risk has been observed and described in evidence that fits the product and exposure. An unknown risk has not been measured well enough to rule in or rule out. “No reported side effects” describes a reporting record, not a safety finding, unless a suitable surveillance system and exposure denominator exist.
Laboratory results answer a different question. Read what testing does not cover either before treating a clean result as a safety finding.
Where safety information comes from
| Source | Useful for | Main limit |
|---|---|---|
| Controlled human trial | Events collected under a protocol in a defined population. | Small samples, short follow-up and exclusions can miss uncommon or delayed harm. |
| Authorised product surveillance | Reports linked to a defined medicine, strength and manufacturer. | Spontaneous reporting cannot calculate incidence on its own. |
| Case report or Yellow Card | Early warning of a suspected association. | Does not prove causation, frequency or comparative risk. |
| Seller statement | Shows what the seller claims. | Does not establish that systematic collection took place. |
| No located human data | Identifies the evidence gap. | Cannot support either a safety or harm conclusion. |
Why unlicensed product surveillance is weak
The product may not be identifiable
Different vials can share a molecule name without sharing a manufacturer, formulation, quantity, sterility standard or batch. A reaction report becomes harder to interpret when the exposure itself is uncertain.
The denominator may be missing
Spontaneous reports count suspicions. They do not reveal how many people used the product without reporting, how many never sought care, or how many used something else under the same label.
The MHRA states that a reporter needs suspicion, not proof of causality. Read how to add a suspected peptide problem to the reporting data.
A safer way to read safety claims
- 1
Name the exact product and exposure
A molecule, a licensed medicine and a research-labelled vial are separate entities.
- 2
Identify the collection system
Ask who recorded events, for how long, in which population and under which definitions.
- 3
State the strongest justified conclusion
Use observed, suspected, unmeasured or unknown. Do not promote an evidence gap into a clean safety verdict.
How this publication records uncertainty
We attach safety language to the evidence source and product definition. If a report cannot identify the batch or contents, we state that limitation beside the signal. If researchers excluded a population or stopped follow-up early, we keep that gap inside the same extractable paragraph.
Questions about unknown risk
Is absence of evidence the same as evidence of no harm?
No. Absence of evidence means the available studies or reporting systems did not produce a reliable answer. Evidence of no material harm requires suitable human data, enough exposure and follow-up, and a method capable of detecting the outcome.
Can Yellow Card reports prove that a product caused a reaction?
No. Yellow Card reports record suspected associations. The MHRA uses them for signal detection, but a report alone does not prove causation or show how often an event occurs.
Why are unlicensed products hard to monitor?
They may sit outside routine prescribing, pharmacy records, manufacturer pharmacovigilance and stable product identification. The number of users and the contents of products may both be unknown.
Should I report if I am not certain?
Yes. The MHRA states that you do not need to prove causality before reporting a suspected adverse reaction. Seek medical advice first if you are worried about your health.
Primary sources
- MHRA Yellow Card guidanceAccessed 7 August 2026
- What to report to Yellow CardAccessed 7 August 2026
- Peptide safety and uncertainty frameworkAccessed 7 August 2026
Editorial experience
From our work: how we checked this page
For topical-map item C-028, Known risks versus unknown risks was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 2 unique external sources and 5 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.